Tags

Type your tag names separated by a space and hit enter

[What is recommended in the treatment of acute myeloid leukemia?]
Internist (Berl) 2019; 60(12):1240-1250I

Abstract

Acute myeloid leukemia (AML) is characterized by a malignant transformation and proliferation of myeloid progenitor cells that cause a replacement of normal hematopoiesis. Diagnostic workup for AML includes cytogenetic analysis and mutational screening covering frequently mutated genes in AML. The genetic analysis is required for risk stratification and treatment decisions. Very recently, three novel drugs have been approved for patients who can be intensively treated: a tyrosine kinase inhibitor (midostaurin) for patients with FLT3 mutations, a liposomal formulation of chemotherapy (CPX) for patients with features of secondary AML, and a CD33 antibody-drug conjugate (gemtuzumab-ozogamicin) for AML with CD33 expression. Allogeneic stem cell transplantation remains an important treatment strategy for patients with intermediate- or high-risk AML and for patients with relapsed AML. For elderly patients who cannot undergo intensive treatment, demethylating agents are the treatment of choice. The aim is to prolong life expectancy with acceptable quality of life. In recent clinical trials, novel drugs have shown promising results in this patient population. Some of these drugs have already been approved in the US. Among these drugs are the Bcl‑2 inhibitor venetoclax, which is already approved in Germany for chronic lymphatic leukemia, as well as IDH1/IDH2 inhibitors (the latter for patients with IDH1/IDH2 mutated AML). Acute promyelocytic leukemia represents a special type of AML that should be treated with a combination of all-trans retinoic acid and arsenic trioxide leading to excellent outcome.

Authors+Show Affiliations

Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. thol.felicitas@mh-hannover.de.

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

31690995

Citation

Thol, F. "[What Is Recommended in the Treatment of Acute Myeloid Leukemia?]." Der Internist, vol. 60, no. 12, 2019, pp. 1240-1250.
Thol F. [What is recommended in the treatment of acute myeloid leukemia?]. Internist (Berl). 2019;60(12):1240-1250.
Thol, F. (2019). [What is recommended in the treatment of acute myeloid leukemia?]. Der Internist, 60(12), pp. 1240-1250. doi:10.1007/s00108-019-00696-w.
Thol F. [What Is Recommended in the Treatment of Acute Myeloid Leukemia?]. Internist (Berl). 2019;60(12):1240-1250. PubMed PMID: 31690995.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [What is recommended in the treatment of acute myeloid leukemia?] A1 - Thol,F, PY - 2019/11/7/pubmed PY - 2019/11/7/medline PY - 2019/11/7/entrez KW - DNA demethylation KW - Leukemia, promyelocytic, acute KW - Molecular diagnostics KW - Molecular targeted therapy KW - Venetoclax SP - 1240 EP - 1250 JF - Der Internist JO - Internist (Berl) VL - 60 IS - 12 N2 - Acute myeloid leukemia (AML) is characterized by a malignant transformation and proliferation of myeloid progenitor cells that cause a replacement of normal hematopoiesis. Diagnostic workup for AML includes cytogenetic analysis and mutational screening covering frequently mutated genes in AML. The genetic analysis is required for risk stratification and treatment decisions. Very recently, three novel drugs have been approved for patients who can be intensively treated: a tyrosine kinase inhibitor (midostaurin) for patients with FLT3 mutations, a liposomal formulation of chemotherapy (CPX) for patients with features of secondary AML, and a CD33 antibody-drug conjugate (gemtuzumab-ozogamicin) for AML with CD33 expression. Allogeneic stem cell transplantation remains an important treatment strategy for patients with intermediate- or high-risk AML and for patients with relapsed AML. For elderly patients who cannot undergo intensive treatment, demethylating agents are the treatment of choice. The aim is to prolong life expectancy with acceptable quality of life. In recent clinical trials, novel drugs have shown promising results in this patient population. Some of these drugs have already been approved in the US. Among these drugs are the Bcl‑2 inhibitor venetoclax, which is already approved in Germany for chronic lymphatic leukemia, as well as IDH1/IDH2 inhibitors (the latter for patients with IDH1/IDH2 mutated AML). Acute promyelocytic leukemia represents a special type of AML that should be treated with a combination of all-trans retinoic acid and arsenic trioxide leading to excellent outcome. SN - 1432-1289 UR - https://www.unboundmedicine.com/medline/citation/31690995/[What_is_recommended_in_the_treatment_of_acute_myeloid_leukemia] L2 - https://dx.doi.org/10.1007/s00108-019-00696-w DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows